Antibiotic resistant Acinetobacter baumannii is susceptible to the novel iron-sequestering anti-infective DIBI in vitro and in experimental pneumonia in mice.

Antibiotic resistant Acinetobacter baumannii is susceptible to the novel iron-sequestering anti-infective DIBI in vitro and in experimental pneumonia in mice. Antimicrob Agents Chemother. 2019 Jun 17;: Authors: Parquet MDC, Savage KA, Allan DS, Ang MTC, Chen W, Logan SM, Holbein BE Abstract Acinetobacter baumannii is a major cause of nosocomial infections especially hospital-acquired pneumonia. This bacterium readily acquires antibiotic resistance traits and therefore, new treatment alternatives are urgently needed. The virulence of A. baumannii linked to iron acquisition suggests a potential for new anti-infectives that target its iron acquisition. DIBI is a purpose-designed, iron-sequestering, anti-microbial that has shown promise for treating microbial infection. DIBI was investigated for its in vitro and in vivo activities against clinical A. baumannii isolates. DIBI was inhibitory for all isolates tested with very low MICs (2 μg/mL equivalent to 0.2 μM), i.e., at or below the typical antibiotic MICs reported for antibiotic sensitive strains. DIBI inhibition is Fe-specific and it caused an iron-restricted bacterial physiology which led to enhanced antibiotic killing by several discrete antibiotics. DIBI also strongly suppressed recovery growth of the surviving population following antibiotic exposure. A low intranasal dose (11 μmol/kg) of DIBI following intranasal challenge with hypervirulent ciprofloxacin (CIP)-resistant A. b...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research